Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.
Esophageal Cancer|Gastroesophageal Junction Cancer
DRUG: Nivolumab
Participant disease-free survival (DFS), Up to 1 year
Participant socio-demographics, Baseline and up to 1 year|Date of tumor initial diagnosis, Baseline|Tumor location at initial diagnosis, Baseline|Tumor histology at initial diagnosis, Baseline|Resected tumor margins status, Negative (clear), positive (involved), close margins, Baseline|Eastern Cooperative Oncology Group (ECOG) performance status, Baseline and up to 1 year|Pathological lymph-node status, Baseline and up to 1 year|Pathological tumor status, Baseline and up to 1 year|Participant biomarkers (if available), Including PD-L1 expression, HER2 status, Epstein-Barr virus positivity, tumor metastasis, Baseline and up to 1 year|Participant outcomes after nivolumab treatment, Including disease stage, recurrence, disease progression, medical imaging test result, and death information, Baseline and up to 1 year|Participant medical history, Baseline and up to 1 year|Participant cancer treatment history, Baseline|Esophageal Cancer (EC) or gastroesophageal junction cancer (GEJC) stage at nivolumab treatment initiation, Day 1|Indication for nivolumab treatment, Day 1|Nivolumab treatment duration, Up to 1 year|Time from surgery to nivolumab initiation, Day 1|Nivolumab treatment regimen, Up to 1 year|Participant concomitant treatment(s), Baseline and up to 1 year|Participant systemic treatment(s), Up to 1 year|Date of nivolumab treatment completion/discontinuation, Up to 1 year|Reasons for treatment discontinuation/cessation, Up to 1 year|Subsequent treatment after nivolumab discontinuation, Up to 1 year|Time to next treatment (TTNT), Up to 1 year|Nivolumab treatment modifications in relation to the management of adverse events (AE), Up to 1 year|Participant distant metastasis-free survival (DMFS), Up to 1 year|Participant distant metastasis-free survival (DMFS) rates, Up to 1 year
The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.